This code system http://terminology.hl7.org/CodeSystem/research-study-phase defines the following codes:
\n \n \n \n \n \n Code\n \n | \n \n \n \n Display\n \n | \n \n \n \n Definition\n \n | \n \n
\n \n \n \n n-a\n \n \n \n | \n \n N/A | \n \n Trials without phases (for example, studies of devices or behavioral interventions). | \n \n
\n \n \n \n early-phase-1\n \n \n \n | \n \n Early Phase 1 | \n \n Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0. | \n \n
\n \n \n \n phase-1\n \n \n \n | \n \n Phase 1 | \n \n Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. | \n \n
\n \n \n \n phase-1-phase-2\n \n \n \n | \n \n Phase 1/Phase 2 | \n \n Trials that are a combination of phases 1 and 2. | \n \n
\n \n \n \n phase-2\n \n \n \n | \n \n Phase 2 | \n \n Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks. | \n \n
\n \n \n \n phase-2-phase-3\n \n \n \n | \n \n Phase 2/Phase 3 | \n \n Trials that are a combination of phases 2 and 3. | \n \n
\n \n \n \n phase-3\n \n \n \n | \n \n Phase 3 | \n \n Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug. | \n \n
\n \n \n \n phase-4\n \n \n \n | \n \n Phase 4 | \n \n Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use. | \n \n
\n \n